The therapeutic effect of Avonex, Rebif and Betaferon on disability and quality of life in multiple sclerosis: A Randomized Clinical Trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201404195280N16

Enrollment

Registered

2014-04-26

Start date

2006-07-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis. Multiple sclerosis

Interventions

Intervention 1: Avonex was administered 30mcg once per week via intramuscular injection. Intervention 2: Rebif was administered 44mcg three times per week via subcutaneous injection. Intervention 3: B

Treatment - Drugs

Avonex was administered 30mcg once per week via intramuscular injection

Rebif was administered 44mcg three times per week via subcutaneous injection

Betaferon was administered 0.25mg every other day via subcutaneous injection.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: newly diagnosed MS subjects. Exclution criteria: had history of substance abuse;treatment with any other type of DMTs ; had any signs of depression.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Disability. Timepoint: baseline and 12 months after treatment. Method of measurement: The expanded disability status scale (EDSS).;Quality of life. Timepoint: baseline and 12 months after treatment. Method of measurement: MSQOL-54 questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Elias Orouji

Ghaem Hospital

pbsrc@mums.ac.ir+98 51 1712 4184

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026